Efficacy and safety of single-dose 2.0g azithromycin in the treatment of acute exacerbation of chronic obstructive pulmonary disease

Asai, Nobuhiro; Ohkuni, Yoshihiro; Iwasaki, Takuya; Matsunuma, Ryo; Nakashima, Kei; Otsuka, Yoshihito; Kaneko, Norihiro

doi:10.1007/s10156-011-0260-z

Cited by 7 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They suggested that the pharmacokinetic profiles of azithromycin are different in GCF and serum 6) . It was also reported that azithromycin attenuates acute and chronic tissue inflammation 4,5,9,10) . A higher concentration of azithromycin into the tooth extraction site is considered beneficial for preventing infection after tooth extraction.…”

Section: Discussionmentioning

confidence: 93%

“…The safety of massive doses of azithromycin is confirmed, and a single-dose of 2.0g of azithromycin can yield a high blood concentration 4,5) . AZ-ER is thought to show high penetration into inflammation tissue 4-6, 9, 10) .…”

Section: Discussionmentioning

confidence: 95%

“…A novel microsphere-based azithromycin extended-release formulation (AZ-ER) allows administration of a high oral dose of azithromycin as single dose regimen, while maintaining tolerability 4,5) . Azithromycin is known as an effective antibiotic in the treatment of odontogenic infections, 6) and the administration of a single large dose of azithromycin as front-loading achieves more rapid bacterial eradication and prophylaxis of postoperative infections including prevention of infective endocarditis 7,8) .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of single-dose extended-release oral azithromycin on anticoagulation status in warfarinized patients

Kusafuka

Kitamura

Sakurai

et al. 2013

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

View full text Add to dashboard Cite

Objective: To investigate the possible influence of single-dose 2.0 g azithromycin (AZ-ER) on anticoagulation in patients taking warfarin.Study design: Eighteen consecutive patients receiving long-term stable warfarin therapy were enrolled in this study. AZ-ER was administered 1-hour prior to tooth extraction.The International Normalized Ratio (INR) value was measured prior to AZ-ER administration, during, one-day after, and seven-days after the tooth extraction.Additionally, the azithromycin concentration in the extraction wound as well as in peripheral venous blood was assessed.Results: The changes in INR throughout the study period were not statistically significant (two-factor ANOVA, N.S.). The azithromycin concentration in extraction wounds was higher than that in peripheral veins. Conclusion:The results of this study suggest that prophylactic administration of AZ-ER to patients receiving daily warfarin therapy with a stable coagulation status has no relevant effect on the anticoagulant effect of warfarin.3

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of single-dose extended-release oral azithromycin on anticoagulation status in warfarinized patients

Kusafuka

Kitamura

Sakurai

et al. 2013

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

View full text Add to dashboard Cite

show abstract

“…Furthermore, in a small retrospective study in Japan, single-dose 2.0 gm azithromycin compared to intravenous antibiotics in hospitalized AECOPD patients resulted in a shorter length of hospital stay. 24 A previous RCT 25 demonstrated that azithromycin treatment within the first two days of infectious AECOPD admission and extended for three months compared to placebo did not reduce all-cause mortality but only tended to reduce mortality by 45% within six days of admission. This observation indicated the potential benefit of macrolide treatment on in-hospital mortality during the early admission period.…”

Section: Discussionmentioning

confidence: 99%

Effect of Macrolide Antibiotics on In-Hospital Mortality Among Acute Exacerbation of COPD Patients: A Propensity Score-Matched Analysis

Morasert¹,

Kriengwattanakul²,

Kulalert³

2022

COPD

View full text Add to dashboard Cite

Objective This study aimed to assess whether the short-term use of macrolide antibiotics during hospitalization can reduce in-hospital all-cause mortality compared to non-macrolide treatment in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A propensity score (PS) matching analysis was performed using retrospective data from the admission records of AECOPD patients in the medical general ward and medical intensive care unit of a tertiary care center between October 2015 and September 2018. The multivariable Cox proportional hazard model was performed to eliminate residual confounding after the PS analysis. Results The mortality rate was 11.1% of 1528 admissions in the PS matching cohort. Approximately 70% of patients had respiratory failure requiring intubation on initial admission, and 34% had pneumonia. Macrolide treatment significantly reduced in-hospital mortality among AECOPD patients (adjusted hazard ratio, 0.55; 95% confidence interval 0.32–0.96; P =0.034). Clarithromycin was the most commonly prescribed macrolide (80%). Conclusion Macrolide antibiotics reduced in-hospital mortality in hospitalized AECOPD patients. The combination of antimicrobial and immunomodulatory effects of macrolide treatment could play an essential role.

show abstract

“…As a result, the patient's respiratory dysfunction and pancytopenia rapidly improved. Some physicians previously reported that macrolides could be effective in preventing and treating acute exacerbation of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) [10,11]. It is evident that macrolides decrease neutrophil chemotaxis and infiltration into the respiratory epithelium down-regulate adhesion molecule expression and enhance neutrophil apoptosis [12,13].…”

Section: Discussionmentioning

confidence: 99%

A case of novel swine influenza A (H1N1) pneumonia complicated with virus-associated hemophagocytic syndrome

Asai

Ohkuni

Matsunuma

et al. 2012

Journal of Infection and Chemotherapy

Self Cite

View full text Add to dashboard Cite

Influenza related to complications such as pneumonia and encephalitis have sporadically been reported. However, influenza A (H1N1)-virus-associated hemophagocytic syndrome (VAHS) has rarely been reported. A 39-year old woman complained of high fever and was referred to us. Chest infiltrations in both lungs and a positive polymerase chain reaction (PCR) for novel swine origin influenza A (H1N1) in bronchial alveolar lavage fluid (BALF) specimen was confirmed and she was diagnosed with influenza A (H1N1) pneumonia. Pancytopenia was found, and hemophagocytic syndrome (HPS) was diagnosed by bone marrow aspiration. Following intravenous administration of antiflu drug and combination therapy of steroid pulse and erythromycin IV, the patient’s respiratory dysfunction and lab data gradually improved and she was discharged on day 21. Whereas secondary HPS related to viral infections such as Epstein–Barr virus, cytomegalovirus, and human herpesvirus type 6 are commonly seen, H1N1 pneumonia complicated with secondary VAHS is rare.

show abstract

Efficacy and safety of single-dose 2.0g azithromycin in the treatment of acute exacerbation of chronic obstructive pulmonary disease

Cited by 7 publications

References 24 publications

Effect of single-dose extended-release oral azithromycin on anticoagulation status in warfarinized patients

Effect of single-dose extended-release oral azithromycin on anticoagulation status in warfarinized patients

Effect of Macrolide Antibiotics on In-Hospital Mortality Among Acute Exacerbation of COPD Patients: A Propensity Score-Matched Analysis

A case of novel swine influenza A (H1N1) pneumonia complicated with virus-associated hemophagocytic syndrome

Contact Info

Product

Resources

About